Table 3. Incidence of colorectal cancer and dysplasia during follow-up in patients with IBD-associated dysplasia.

	Present study	Mohan et al (2020) 2	Wanders et al (2014) 21	Thomas et al (2007) 20
No. of included studies	11	18	10	20
No. of patients (n)	506	1037	376	508
Inclusion criteria
Study population	UC or CD with any dysplasia size > 10 mm	UC + CD with any dysplasia	UC with any dysplasia	UC with only LGD
Intervention	EMR, ESD, hybrid ESD	Simple polypectomy, EMR, ESD or hybrid	Simple polypectomy	Surveillance colonoscopy or colectomy
Lesion characteristics (%)	Non-polypoid (67.7) polypoid (32.3)	Non-polypoid (25) Polypoid (9.4) Non-polypoid + Polypoid (65.4)	Polypoid (100)	Non-polypoid (93.8) Polypoid (6.1)
Follow-up period (person-years)	1514	NA	1704	1520
Polyp size (cm)	2.3 (mean)	NA	0.5–1.2	NA
Incidence of any dysplastic lesion (per 1000 person-years)	56 (95 % CI, 33–97)	43 (95 % CI, 30–57)	65 (95 % CI, 54–78)	NA
Incidence of HGD/CRC (per 1000 person-years)	15 (95 % CI: 7–32)	NA	7.0 (95 % CI, 4.0–12.4)	30 (95 % CI, 12–76)
Incidence of CRC 1 (per 1000 person-years)	NA	2 (95 % CI: 0–3)	5.3 (95 % CI, 2.7–10.1)	14 (95 % CI, 5–34)

IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; LGD, low-grade dysplasia; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; HGD, high-grade dysplasia; CRC, colorectal cancer; CI, confidence interval.

¹Unable to report incidence of CRC per 1000 person years in the present study because of a very low event rate; overall 0.2 % CRC was detected during the surveillance period. IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; LGD, low-grade dysplasia; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; HGD, high-grade dysplasia; CRC, colorectal cancer; CI, confidence interval.